TY - JOUR
T1 - Are clinical guidelines for the management of intraductal papillary mucinous neoplasms followed?
T2 - A single-center analysis
AU - Tabrizian, Parissa
AU - Berger, Yaniv
AU - Pierobon, Elisa Sefora
AU - Aycart, Samantha
AU - Argiriadi, Pamela
AU - Fei, Kezhen
AU - Carrasco-Avino, Gonzalo
AU - Labow, Daniel M.
AU - Sarpel, Umut
N1 - Publisher Copyright:
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Objectives: This study aimed to determine how frequently guidelines for the management of intraductal papillarymucinous neoplasms (IPMNs) are followed and establish factors associated with failure. Methods: Four hundred forty-five patientswith radiographic diagnosis of IPMN 1 cm or greater between January 1, 2003 and January 1, 2013 were included. We defined failure of guideline adherence if the following occurred: (a) failure of acknowledgment of IPMN, (b) failure to undergo endoscopic ultrasound, (c) failure to undergo resection, or (d) failure to undergo at least 1 surveillance image within 2 years after diagnosis. Results: Failure of guideline adherence was observed in 58% of patients and evident across all the respective criteria (A: 38%, B: 25%, C: 29%, D: 33%). Age older than 68 years (P < 0.01), American Society of Anesthesiologists score of 3 or higher (P < 0.0001), benign findings on imaging (P < 0.0001), and major comorbid conditions (P < 0.01) were factors associated with higher rate of failure to compliance. On multivariate logistic regression, American Society of Anesthesiologists score of 3 or higher and benign features were associated with 4.0 times (95% confidence interval, 2.02-8.06) and 2.6 times (95% confidence interval, 1.60-4.07) higher odds of failure to compliance with guidelines, respectively. Conclusions: Compliance with clinical guidelines for the management of IPMN is poor. Socioeconomic factors do not seem to create a disparity to care. However, many patients with IPMN have other medical diagnoses that take priority over IPMN surveillance and treatment.
AB - Objectives: This study aimed to determine how frequently guidelines for the management of intraductal papillarymucinous neoplasms (IPMNs) are followed and establish factors associated with failure. Methods: Four hundred forty-five patientswith radiographic diagnosis of IPMN 1 cm or greater between January 1, 2003 and January 1, 2013 were included. We defined failure of guideline adherence if the following occurred: (a) failure of acknowledgment of IPMN, (b) failure to undergo endoscopic ultrasound, (c) failure to undergo resection, or (d) failure to undergo at least 1 surveillance image within 2 years after diagnosis. Results: Failure of guideline adherence was observed in 58% of patients and evident across all the respective criteria (A: 38%, B: 25%, C: 29%, D: 33%). Age older than 68 years (P < 0.01), American Society of Anesthesiologists score of 3 or higher (P < 0.0001), benign findings on imaging (P < 0.0001), and major comorbid conditions (P < 0.01) were factors associated with higher rate of failure to compliance. On multivariate logistic regression, American Society of Anesthesiologists score of 3 or higher and benign features were associated with 4.0 times (95% confidence interval, 2.02-8.06) and 2.6 times (95% confidence interval, 1.60-4.07) higher odds of failure to compliance with guidelines, respectively. Conclusions: Compliance with clinical guidelines for the management of IPMN is poor. Socioeconomic factors do not seem to create a disparity to care. However, many patients with IPMN have other medical diagnoses that take priority over IPMN surveillance and treatment.
KW - Clinical guidelines
KW - Intraductal papillary mucinous neoplasms
KW - Management
KW - Socioeconomic disparity
UR - http://www.scopus.com/inward/record.url?scp=85008312097&partnerID=8YFLogxK
U2 - 10.1097/MPA.0000000000000747
DO - 10.1097/MPA.0000000000000747
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 28060184
AN - SCOPUS:85008312097
SN - 0885-3177
VL - 46
SP - 198
EP - 202
JO - Pancreas
JF - Pancreas
IS - 2
ER -